Anti-science case study: COVID-19 vaccines' effectiveness and safety exaggerated.
作者信息
Lataster Raphael
机构信息
University of Sydney, Sydney, Australia.
出版信息
Public Health Pract (Oxf). 2024 May 23;7:100517. doi: 10.1016/j.puhip.2024.100517. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Anti-science case study: COVID-19 vaccines' effectiveness and safety exaggerated.反科学案例研究：新冠疫苗的有效性和安全性被夸大。
Public Health Pract (Oxf). 2024 May 23;7:100517. doi: 10.1016/j.puhip.2024.100517. eCollection 2024 Jun.
2
[Application of epidemiology research in evaluations of COVID-19 vaccines in both clinical trial and clinical use].[流行病学研究在新型冠状病毒肺炎疫苗临床试验及临床应用评价中的应用]
Zhonghua Liu Xing Bing Xue Za Zhi. 2022 Jan 10;43(1):7-13. doi: 10.3760/cma.j.cn112338-20210902-00705.
3
Exploring future perspectives and pipeline progression in vaccine research and development.探索疫苗研发的未来前景和管线进展。
Ann Ig. 2024 Jul-Aug;36(4):446-461. doi: 10.7416/ai.2024.2614. Epub 2024 Mar 1.
4
Who is "anti-science"?谁是“反科学者”？
Public Health Pract (Oxf). 2024 Mar 29;7:100493. doi: 10.1016/j.puhip.2024.100493. eCollection 2024 Jun.
5
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.mRNA 和阿斯利康 COVID-19 疫苗在自身免疫性风湿病患者中的疗效和安全性：一项系统评价。
Vaccine. 2023 Jun 13;41(26):3801-3812. doi: 10.1016/j.vaccine.2023.05.048. Epub 2023 May 22.
6
COVID-19 Vaccines' Protection Over Time and the Need for Booster Doses; a Systematic Review.新冠疫苗的长期保护作用及加强针需求；一项系统评价
Arch Acad Emerg Med. 2022 Jul 4;10(1):e53. doi: 10.22037/aaem.v10i1.1582. eCollection 2022.
7
Forty days of regulatory emergency use authorisation of COVID-19 vaccines: Interfacing efficacy, hesitancy and SDG target 3.8.COVID-19 疫苗监管应急使用授权 40 天：对接功效、犹豫和可持续发展目标 3.8。
Glob Public Health. 2021 Oct;16(10):1537-1558. doi: 10.1080/17441692.2021.1938170. Epub 2021 Jun 9.
8
COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.以色列成年人在疫苗可获得前后对 COVID-19 疫苗的犹豫：一项横断面全国调查。
Vaccine. 2022 Oct 12;40(43):6271-6276. doi: 10.1016/j.vaccine.2022.08.070. Epub 2022 Sep 14.
9
Heterologous prime-boost strategies for COVID-19 vaccines.用于 COVID-19 疫苗的异源初免-加强策略。
J Travel Med. 2022 May 31;29(3). doi: 10.1093/jtm/taab191.
10
Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 infections among healthcare personnel in Pakistan: a test-negative case-control study.在巴基斯坦，医护人员中 COVID-19 灭活疫苗对 SARS-CoV-2 感染的有效性：一项病例对照研究。
BMJ Open. 2023 Jun 27;13(6):e071789. doi: 10.1136/bmjopen-2023-071789.
引用本文的文献
1
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?从新冠疫情管理中可以吸取哪些教训？
Int J Public Health. 2025 May 30;70:1607727. doi: 10.3389/ijph.2025.1607727. eCollection 2025.
2
Amid Growing Evidence of Conflicts of Interest and Obdurate Groupthink in Medical Journals, Researchers Must Entertain Contrarian Ideas.在医学期刊中，利益冲突和顽固的群体思维的证据越来越多，研究人员必须接受相反的观点。
Cureus. 2025 Jan 23;17(1):e77895. doi: 10.7759/cureus.77895. eCollection 2025 Jan.
本文引用的文献
1
Who is "anti-science"?谁是“反科学者”？
Public Health Pract (Oxf). 2024 Mar 29;7:100493. doi: 10.1016/j.puhip.2024.100493. eCollection 2024 Jun.
2
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.COVID-19 疫苗不良反应的频率和时间；一项多国家队列事件监测研究。
Vaccine. 2024 Apr 2;42(9):2357-2369. doi: 10.1016/j.vaccine.2024.03.001. Epub 2024 Mar 6.
3
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.COVID-19 疫苗和特殊关注的不良事件：一项涉及 9900 万接种者的多国全球疫苗数据网络（GVDN）队列研究。
Vaccine. 2024 Apr 2;42(9):2200-2211. doi: 10.1016/j.vaccine.2024.01.100. Epub 2024 Feb 12.
4
How the adverse effect counting window affected vaccine safety calculations in randomised trials of COVID-19 vaccines.在新冠疫苗随机试验中，不良反应计数窗口如何影响疫苗安全性计算。
J Eval Clin Pract. 2024 Apr;30(3):453-458. doi: 10.1111/jep.13962. Epub 2024 Jan 18.
5
How the case counting window affected vaccine efficacy calculations in randomized trials of COVID-19 vaccines.病例计数窗口如何影响新冠疫苗随机试验中的疫苗效力计算。
J Eval Clin Pract. 2024 Feb;30(1):105-106. doi: 10.1111/jep.13900. Epub 2023 Jul 15.
6
Reply to Fung et al. on COVID-19 vaccine case-counting window biases overstating vaccine effectiveness.对冯等人关于新冠疫苗病例计数窗口偏差夸大疫苗有效性的回复。
J Eval Clin Pract. 2024 Feb;30(1):82-85. doi: 10.1111/jep.13892. Epub 2023 Jul 4.
7
Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects?新型冠状病毒肺炎疫苗的随机临床试验：腺病毒载体疫苗是否具有有益的非特异性效应？
iScience. 2023 May 19;26(5):106733. doi: 10.1016/j.isci.2023.106733. Epub 2023 Apr 25.
8
Sources of bias in observational studies of covid-19 vaccine effectiveness.新冠病毒 19 疫苗有效性观察性研究中的偏倚来源。
J Eval Clin Pract. 2024 Feb;30(1):30-36. doi: 10.1111/jep.13839. Epub 2023 Mar 26.
9
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.mRNA COVID-19 疫苗接种后在成人随机试验中特别关注的严重不良事件。
Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31.
10
Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial.新冠疫情：研究人员揭露辉瑞疫苗试验中的数据完整性问题。
BMJ. 2021 Nov 2;375:n2635. doi: 10.1136/bmj.n2635.
Zotero 插件